Evidence map›Paper›PMID 29017051›Full record

ArticleCancer cell2017

Tumor Suppression by p53: Bring in the Hippo!

Yael Aylon, Moshe Oren

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Frontiers in oncology · 2021
    Article
  4. Cucurbitacin B Inhibits the Hippo-YAP Signaling Pathway and Exerts Anticancer Activity in Colorectal Cancer Cells.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yael AylonDepartment of Molecular Cell Biology, The Weizmann Institute, Rehovot 76100, Israel. Electronic address: yael.aylon@weizmann.ac.il.
Moshe OrenDepartment of Molecular Cell Biology, The Weizmann Institute, Rehovot 76100, Israel. Electronic address: moshe.oren@weizmann.ac.il.
Weizmann Institute of Science · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue of Cancer Cell, Mello et al. investigated how p53 suppresses pancreatic cancer and discovered a key role for the tyrosine phosphatase PTPN14, a p53 transcriptional target. PTPN14 restrains YAP, curbing its potential oncogenic effects. The p53-PTPN14-YAP axis highlights the importance of signaling pathway coordination in cancer prevention.

Indexed as

Pancreatic NeoplasmsTumor Suppressor Protein p53Hippo Signaling PathwayHumansOncogenesPhosphoproteinsProtein Serine-Threonine KinasesProtein Tyrosine Phosphatases, Non-ReceptorSignal TransductionPhosphoproteinsProtein Serine-Threonine KinasesProtein Tyrosine Phosphatases, Non-ReceptorPTPN14 protein, humanTumor Suppressor Protein p53

Identifiers

PMID29017051
OpenAlexW2760898397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.